Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Z160. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1B known ✓ | Q00975 | 14/20 | 1.00 |
| ▸ | CACNA2D1 | P54289 | 15/20 | 1.00 |
| ▸ | CACNB1 | Q02641 | 15/20 | 1.00 |
| ▸ | CACNA1C | Q13936 | 10/20 | 1.00 |
| ▸ | CACNA1H | O95180 | 1/20 | 1.00 |
| ▸ | CACNA1G | O43497 | 4/20 | 0.84 |
| ▸ | CACNA1A | O00555 | 2/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5266285 | 0.93 | CACNA2D1 (0.86) | CACNA2D1CACNB1CACNA1BCACNA1CCACNA1H | |
| SCHEMBL5268519 | 0.92 | CACNA2D1 (1.00) | CACNA2D1CACNB1CACNA1BCACNA1CCACNA1H | |
| SCHEMBL5264907 | 0.92 | CACNA2D1 (1.00) | CACNA2D1CACNB1CACNA1BCACNA1CCACNA1H | |
| SCHEMBL5266301 | 0.92 | CACNA2D1 (1.00) | CACNA2D1CACNB1CACNA1BCACNA1CCACNA1H | |
| SCHEMBL5265406 | 0.92 | CACNA2D1 (1.00) | CACNA2D1CACNB1CACNA1BCACNA1CCACNA1H | |
| SCHEMBL4179713 | 0.92 | CACNA2D1 (1.00) | CACNA2D1CACNB1CACNA1BCACNA1CCACNA1H | |
| SCHEMBL26330969 | 0.90 | CACNA2D1 (0.81) | CACNA2D1CACNB1CACNA1BCACNA1CCACNA1H | |
| SCHEMBL5266814 | 0.89 | CACNA2D1 (1.00) | CACNA2D1CACNB1CACNA1BCACNA1CCACNA1H | |
| SCHEMBL5265070 | 0.88 | CACNA2D1 (1.00) | CACNA2D1CACNB1CACNA1BCACNA1CCACNA1H | |
| SCHEMBL8427763 | 0.88 | CACNA2D1 (1.00) | CACNA2D1CACNB1CACNA1BCACNA1CCACNA1H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 110 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8591944-B2 | Solid dispersion formulations and methods of use thereof | ZALICUS PHARMACEUTICALS LTD. (CA) | 2013-11-26 | — | — | US | claimed |
| US-20130231350-A1 | SOLID DISPERSION FORMULATIONS AND METHODS OF USE THEREOF | ZALICUS PHARMACEUTICALS LTD. (US) | 2013-09-05 | — | — | US | claimed |
| US-8409560-B2 | Solid dispersion formulations and methods of use thereof | ZALICUS PHARMACEUTICALS LTD. (CA) | 2013-04-02 | — | — | US | claimed |
| US-8362021-B2 | Method for increasing the bioavailability of benzhydryl piperazine containing compounds | ZALICUS PHARMACEUTICALS LTD. (CA) | 2013-01-29 | — | — | US | claimed |
| US-20090312346-A1 | METHOD FOR INCREASING THE BIOAVAILABILITY OF BENZHYDRYL PIPERAZINE CONTAINING COMPOUNDS | NEUROMED PHARMACEUTICALS LTD. (CA) | 2009-12-17 | — | — | US | claimed |
| EP-2019676-A2 | METHOD FOR INCREASING THE BIOAVAILABILITY OF BENZHYDRYL PIPERAZINE CONTAINING COMPOUNDS | Neuromed Pharmaceuticals, Ltd. (CA) | 2009-02-04 | — | — | EP | claimed |
| US-20080300262-A1 | Combination Therapy for Relief of Pain | ZALICUS PHARMACEUTICALS LTD. (CA) | 2008-12-04 | — | — | US | claimed |
| EP-1871372-A1 | COMBINATION THERAPY COMPRISING AN N-TYPE CALCIUM CHANNEL BLOCKER FOR THE ALLEVIATION OF PAIN | Neuromed Pharmaceuticals, Ltd. (CA) | 2008-01-02 | — | — | EP | claimed |
| WO-2007133481-A2 | METHOD FOR INCREASING THE BIOAVAILABILITY OF BENZHYDRYL PIPERAZINE CONTAINING COMPOUNDS | NEUROMED PHARMACEUTICALS LTD. (CA) | 2007-11-22 | — | — | WO | claimed |
| WO-2006105670-A1 | COMBINATION THERAPY COMPRISING AN N-TYPE CALCIUM CHANNEL BLOCKER FOR THE ALLEVIATION OF PAIN | NEUROMED PHARMACEUTICALS LTD. (CA) | 2006-10-12 | — | — | WO | claimed |
| EP-1091737-B1 | Use of 1-(3,3-diphenylpropionyl)-4-benzhydril piperazine in the treatment of pain | NEUROMED TECH INC (CA) | 2005-09-14 | — | — | EP | claimed |
| US-12637455-B2 | Naphthyridine and pyrido[3,4-c]pyridazine derivatives as GABAA α5 receptor modulators | RICHTER GEDEON NYRT. (HU) | 2026-05-26 | — | — | US | disclosed |
| US-12534458-B2 | Spiropiperidine allosteric modulators of nicotinic acetylcholine receptors | MERCK SHARP & DOHME LLC (US) | 2026-01-27 | — | — | US | disclosed |
| EP-3856342-B1 | BICYCLIC DERIVATIVES AS GABAA A5 RECEPTOR MODULATORS | RICHTER GEDEON NYRT (HU) | 2025-12-10 | — | — | EP | disclosed |
| US-12370182-B2 | Bicyclic derivatives as GABAA A5 receptor modulators | RICHTER GEDEON NYRT. (HU) | 2025-07-29 | — | — | US | disclosed |
| US-20040259866-A1 | Calcium channel blockers comprising two benzhydril moieties | ZALICUS PHARMACEUTICALS LTD. (CA) | 2004-12-23 | — | — | US | disclosed |
| US-20040259866-A1 | Calcium channel blockers comprising two benzhydril moieties | ZALICUS PHARMACEUTICALS LTD. (CA) | 2004-12-23 | — | — | US | disclosed |
| US-20040209872-A1 | Calcium channel blockers comprising two benzhydril moieties | ZALICUS PHARMACEUTICALS LTD. (CA) | 2004-10-21 | — | — | US | disclosed |
| US-20040209872-A1 | Calcium channel blockers comprising two benzhydril moieties | ZALICUS PHARMACEUTICALS LTD. (CA) | 2004-10-21 | — | — | US | disclosed |
| US-20040034035-A1 | Calcium channel inhibitors comprising benzhydril spaced from piperazine | NEUROMED TECHNOLOGIES, INC. | 2004-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12534458-B2 | Spiropiperidine allosteric modulators of nicotinic acetylcholine receptors | CHRNA6, CHRNA7, CHRNA5 | CACNA1B 297/4885CACNA2D1 911/4885CACNB1 492/4885 |
| US-12370182-B2 | Bicyclic derivatives as GABAA A5 receptor modulators | GABRA5, GABRA1, GABRB1 | CACNA1B 341/4885CACNA2D1 386/4885CACNB1 402/4885 |
| US-20040209872-A1 | Calcium channel blockers comprising two benzhydril moieties | CACNA1C, CACNA1F, CACNA1D | CACNA1B 4/4885CACNA2D1 41/4885CACNB1 14/4885 |
| US-20130231350-A1 | SOLID DISPERSION FORMULATIONS AND METHODS OF USE THEREOF | SLC6A7, SLC6A1, PRNP | CACNA1B 1368/4885CACNA2D1 3684/4885CACNB1 1597/4885 |
| US-20040259866-A1 | Calcium channel blockers comprising two benzhydril moieties | CACNA1C, CACNA1F, CACNA1D | CACNA1B 4/4885CACNA2D1 41/4885CACNB1 14/4885 |
| US-12637455-B2 | Naphthyridine and pyrido[3,4-c]pyridazine derivatives as GABAA α5 receptor modulators | GABRA5, GABRA1, GABRB1 | CACNA1B 293/4885CACNA2D1 248/4885CACNB1 401/4885 |
| US-20080300262-A1 | Combination Therapy for Relief of Pain | CACNA1B, TRPV1, ORAI1 | CACNA1B 1/4885CACNA2D1 90/4885CACNB1 4/4885 |
| US-20040034035-A1 | Calcium channel inhibitors comprising benzhydril spaced from piperazine | CACNA1C, CACNA1F, CACNA1D | CACNA1B 6/4885CACNA2D1 30/4885CACNB1 14/4885 |
| US-20090312346-A1 | METHOD FOR INCREASING THE BIOAVAILABILITY OF BENZHYDRYL PIPERAZINE CONTAINING COMPOUNDS | SLC7A1, SLC10A2, SLC10A1 | CACNA1B 993/4885CACNA2D1 3029/4885CACNB1 1150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.